Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00555022 |
GSK1160724 is a potent mAChR antagonist, which is being developed for treatment of chronic obstructive pulmonary disease (COPD)
Condition | Intervention | Phase |
---|---|---|
Chronic Obstructive Pulmonary Disease (COPD) |
Drug: GSK1160724 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Crossover Assignment, Safety Study |
Official Title: | A Randomized Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK1160724 and Tiotropium Bromide |
Enrollment: | 20 |
Study Start Date: | December 2007 |
Study Completion Date: | April 2008 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
The subject has taken:
United Kingdom, Middlesex | |
GSK Investigational Site | |
Harrow, Middlesex, United Kingdom, HA1 3UJ |
Study Director: | GSK Clinical Trials, MD, MSc, FFPM | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | AC5108696 |
Study First Received: | November 6, 2007 |
Last Updated: | October 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00555022 |
Health Authority: | United Kingdom: National Research Ethics Service (NRES) |
Muscarinic Receptor Antagonist, Anticholinergic, COPD, FTIH, Plethysmography |
Lung Diseases, Obstructive Respiratory Tract Diseases Bromides Lung Diseases |
Healthy Tiotropium Pulmonary Disease, Chronic Obstructive |